Posters
« Back
The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
EP28949
Poster Title: The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
Submitted on 14 Aug 2018
Author(s): SJ Sukoff Rizzo1, SK Quinney2, KD Onos1, KJ Keezer1, DR Jones2, AR Masters2, IF Metzger2, JA Meyer2, J Peters2, SC Persohn2, BR McCarthy2, AA Riley2, M Sasner1, G Howell1, H Williams1, AJ Oblak2, BL Lamb2, and PR Territo2
Affiliations: 1The Jackson Laboratory, Bar Harbor, Maine USA; 2Indiana University School of Medicine, Indianapolis, Indiana USA
This poster was presented at AAIC 2018
Poster Views: 723
View poster »


Poster Information
Abstract: The preclinical testing core (PTC) of the Model Organism Development for Late Onset Alzheimer’s Disease (MODEL-AD) consortium has established a streamlined preclinical drug testing strategy with go/no-go decision points that allow critical and unbiased assessments of potential therapeutic agents. The goals of the PTC are to develop a testing strategy that maximizes the therapeutic potential of all drug candidates by initiating the dosing strategy prior to the onset of disease relevant biomarker readouts.
The PTC strategy includes a primary screen to determine: 1) drug formulation; 2) drug stability; and 3) in vivo pharmacokinetics and target tissue concentrations in models at disease-relevant ages. A secondary screen evaluates target engagement and disease modifying activity utilizing non-invasive PET/MRI as a pharmacodynamic (PD) readout matched to known disease pathology in the model. Compounds demonstrating positive PD effects in the secondary screen are further interrogated via a tertiary screen of functional assays that assess the compounds ability to normalize a disease-related phenotype in cognition and neurophysiological tests. For the present studies, we selected levetiracetam (LEV), a compound currently in clinical trials for the treatment of cognitive impairment associated with AD, for testing in 5XFAD mice.
Summary: The PTC pipeline for MODEL-AD using levetiracetam as a pipeline testing compound.Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Etiological diagnostics of cardiomyopathies in the cardiology unit of the HUEH internal medicine department during the period from 8 January 2014 to 14 June 2014
*Axler JEAN PAUL; **Lesly Ed. ARCHER; *Raema Mimrod JEAN; *Gerald VERNELUS; *Rodolph MALEBRANCHE

Medical Student: Move over Stem Cells – Exosomes are Here! What are Exosomes & their role in Regenerative Medicine?
Amartej Singh Deol MD4 & Advisor: Shivinder S. Deol MD

Resident: NONHEALING ULCER THE NEED TO LOOK FURTHER
Briand Bounkeu MD; Ravi Shekarappa MD; La Toya Jackson DO, FAAFP; Chinedu Ivonye MD, FACP; Cristal Kudiwu MD

Striving for Equity in Surgical, Anesthesia, and Obstetric Research in Haiti: A Multi-Partner, International Research Training Collaboration
Dr. Jean Alouidor*, Dr. Frédéric Barau Déjean*, Dr. Louis-Franck Télémaque, Dr. Ronald Eveillard, Dr. Laëlle Mangurat, Dr. Isaac Martineau, Dr. Chartelin Jean Isaac, Dr. Darlène Rochelin Paultre, Carine Réveil Jean-Baptiste, Dr. Lucile Louis Riché, Dr. Jordan Pyda, Rolvix Patterson III, Dr. Blake Alkire, Dr. Eunice Dérivois-Mérisier (*Co-First Authors)

Projektstatus: Entwicklung einer konsensbasierten Therapieempfehlung für die PADOVAN-METHODE® in der Neurorehabilitation
Eisenmeier, Dimitri1; Ostermann, Thomas1; Vogel, Hannah1; Fetz, Katharina1